Search
KAI-1678
go.drugbank.com/drugs/DB16211InvestigationalKAI-1678 is under investigation in clinical trial NCT01106716 (Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia).
Categories: Protein Kinase C-epsilon, antagonists & inhibitorsLadostigil
go.drugbank.com/drugs/DB16213InvestigationalLadostigil is under investigation in clinical trial NCT01429623 (A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment).
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesLandipirdine
go.drugbank.com/drugs/DB16214InvestigationalLandipirdine is under investigation in clinical trial NCT02258152 (SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)).
Categories: Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor AntagonistsLapaquistat
go.drugbank.com/drugs/DB16215InvestigationalLapaquistat is under investigation in clinical trial NCT00256178 (Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.).
Categories: Heterocyclic Compounds, 1-RingLerociclib
go.drugbank.com/drugs/DB16218InvestigationalLerociclib is under investigation in clinical trial NCT02983071 (G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-positive, Her2-negative Locally Advanced or Metastatic Breast
Lonapegsomatropin
go.drugbank.com/drugs/DB16220ApprovedInvestigationalLonapegsomatropin, also known as TransCon hGH or ACP 001, is a methoxypegylated prodrug of human growth hormone ([somatropin]) indicated for the treatment of children 1 year and older, weighing at least … [A237605,L36380,L36405] Unlike somatropin, which requires daily dosing, lonapegsomatropin can be administered as a single weekly dose.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InducersLoncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigationalRelapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. … [L45206] This therapy was developed by ADC Therapeutics and its accelerated approval for relapsed or refractory B-cell lymphoma is based on promising results from the LOTIS-2 clinical trial.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSynonyms: Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through A protease cleavable valine-alanine linkerLunasine
go.drugbank.com/drugs/DB16223InvestigationalLunasine is under investigation in clinical trial NCT02709330 (ALS Reversals - Lunasin Regimen).
Mavelertinib
go.drugbank.com/drugs/DB16228InvestigationalMavelertinib is under investigation in clinical trial NCT02349633 (Study for Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)).
Mesdopetam
go.drugbank.com/drugs/DB16229InvestigationalMesdopetam is under investigation in clinical trial NCT04435431 (A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia).